- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.09. | Exozymes gibt Termin für Hauptversammlung 2026 und Stichtag bekannt | 2 | Investing.com Deutsch | ||
| 18.09. | EXOZYMES INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.09. | exozymes partners with Curia for NCT manufacturing scale-up | 2 | Investing.com | ||
| 08.09. | eXoZymes und Curia kooperieren bei der Skalierung der NCT-Produktion | 2 | Investing.com Deutsch | ||
| 08.09. | eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT | 371 | ACCESS Newswire | Program expected to commence in Q4 2026 and establish a roadmap for larger-scale production in 2027 LOS ANGELES, CA / ACCESS Newswire / September 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes")... ► Artikel lesen | |
| 20.08. | eXoZymes reports Q2 results | 1 | Seeking Alpha | ||
| 20.08. | eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today | 596 | ACCESS Newswire | Management to host Q2 2026 update at 5PM ET / 2PM PT, today. LOS ANGELES, CA / ACCESS Newswire / August 20, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes... ► Artikel lesen | |
| EXOZYMES Aktie jetzt für 0€ handeln | |||||
| 18.08. | exoZymes reports 10-fold productivity gain in NCT manufacturing | 1 | Investing.com | ||
| 18.08. | eXoZymes meldet zehnfache Produktivitätssteigerung bei der NCT-Herstellung | 1 | Investing.com Deutsch | ||
| 18.08. | eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets | 418 | ACCESS Newswire | Optimized process delivered a 10-fold improvement in productivity, significantly improving the estimated economics of future commercial-scale manufacturing.Estimated manufacturing cost equivalent has... ► Artikel lesen | |
| 13.08. | EXOZYMES INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026 | 518 | ACCESS Newswire | Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar... ► Artikel lesen | |
| 23.07. | eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing | 503 | ACCESS Newswire | Company to collaborate with Lawrence Berkeley National Laboratory on AI-enabled digital twins designed to accelerate optimization of enzyme-driven manufacturing processes.The 9-month project awarded... ► Artikel lesen | |
| 26.06. | eXoZymes erhält 2 Millionen US-Dollar vom NIH zur Weiterentwicklung von Cannabinoid-Analoga für die Arzneimittelforschung | 1 | Bionity.com | ||
| 26.06. | EXOZYMES INC. - 8-K, Current Report | - | SEC Filings | ||
| 24.06. | Cannabinoid-Forschung: eXoZymes sichert sich NIH-Zuschuss über 2 Millionen US-Dollar | 1 | Investing.com Deutsch | ||
| 24.06. | exoZymes receives $2M NIH grant for cannabinoid research | 1 | Investing.com | ||
| 24.06. | eXoZymes awarded $2M NIH Grant to advance cannabinoid analogs for drug discovery | 2 | Seeking Alpha | ||
| 24.06. | eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery | 455 | ACCESS Newswire | Award allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential future pharmaceutical assets and validates the Company's ability to make rare cannabinoids and new... ► Artikel lesen | |
| 17.06. | EXOZYMES INC. - 8-K, Current Report | 1 | SEC Filings |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 9,570 | +0,21 % | Novavax Inc mit SCHOCK-MELDUNG: Meine brandneue Prognose ändert einfach alles - Das dürfen Sie nicht verpassen! | ||
| INOVIO PHARMACEUTICALS | 1,004 | -0,79 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| INFLARX | 1,685 | +2,43 % | InflaRx NV ÜBERRASCHT Anleger: Verkaufen Insider bereits? - Dringend vor Börsenschluss handeln! | ||
| INTELLIA THERAPEUTICS | 10,540 | -0,75 % | Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity | ||
| EDITAS MEDICINE | 2,300 | +0,44 % | Editas raised to Buy at Guggenheim on cholesterol therapy | ||
| NUREXONE BIOLOGIC | 0,407 | +3,30 % | 220 Millionen US-Dollar bis 2033: Warum Moderna, Capricor und NurExone auf die richtige Wirkstoffhülle setzen | ||
| IBIO | 1,017 | -1,93 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| GERON | 1,100 | +0,37 % | Geron Corporation: Geron Announces Appointment of Chinmaya Rath as Chief Business Officer | FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| IMMUNITYBIO | 7,800 | +0,26 % | ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10% | ||
| IMMATICS | 7,610 | +0,86 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MYRIAD GENETICS | 3,736 | 0,00 % | Myriad Genetics, Inc.: Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial | SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been... ► Artikel lesen | |
| MANNKIND | 2,917 | -1,15 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| GINKGO BIOWORKS | 10,300 | -2,46 % | Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab | Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business
BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo... ► Artikel lesen | |
| IMMUNIC | 8,000 | +1,57 % | EQS-News: Immunic AG: Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
02.09.2026 / 12:30 CET/CEST
The issuer... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 6,020 | -1,39 % | Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes | Repurchase reduces unsecured note balance to approximately $364.7 millionManagement to discuss this key milestone and broader transformation progress at upcoming investor conferences GAITHERSBURG... ► Artikel lesen |
Das Unternehmen EXOZYMES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 6,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXOZYMES INC finden Sie auf Wallstreet Online.